Changes of Number and Function of Late Endothelial Progenitor Cells in Peripheral Blood of COPD Patients Combined with Pulmonary Hypertension

Abstract

Objective The objective of this study was to investigate the changes of number and function of late endothelial progenitor cells (EPCs) in peripheral blood of chronic obstructive pulmonary disease (COPD) patients combined with pulmonary hypertension.

Subjects and Methods The study enrolled 120 cases including 40 non-COPD and pulmonary arterial hypertension (PAH) patients (non-COPD group), 40 COPD non-PAH patients (COPD group), and 40 COPD patients combined with PAH (COPD + PAH group). Peripheral blood mononuclear cells were separated by density gradient centrifugation, cultured for 21 days, and then identified as late endothelial progenitor cells. The cell colonies were counted. MTT assay, modified Boyden chamber assay, and human fibronectin plates were used to measure the proliferation, migration, and adhesion functions of the late endothelial progenitor cells, respectively.

Results Compared with non-COPD and COPD groups, the number of peripheral blood late EPCs in COPD + PAH group was significantly reduced, and the proliferation, adhesion, and migration capacities were significantly lowered; the differences were statistically significant (p < 0.05). The number and function of late EPCs decreased with the increase of pulmonary artery pressure (p < 0.05).

Conclusion The number of late EPCs in COPD patients combined with pulmonary hypertension was reduced, which implies the impaired cell functions. The changes of number and function were negatively correlated with the severity of pulmonary hypertension.

Keywords

chronic obstructive pulmonary disease - pulmonary hypertension - late EPCs

• References

• 1 Asahara T, Murohara T, Sullivan A , et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275 (5302) 964-967
• 2 Kwon SM, Lee YK, Yokoyama A , et al. Differential activity of bone marrow hematopoietic stem cell subpopulations for EPC development and ischemic neovascularization. J Mol Cell Cardiol 2011; 51 (3) 308-317
• 3 Hur J, Yoon CH, Kim HS , et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24 (2) 288-293
• 4 Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70 (4) 657-662
• 5 Werner N, Kosiol S, Schiegl T , et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353 (10) 999-1007
• 6 Hill JM, Zalos G, Halcox JP , et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348 (7) 593-600
• 7 Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105 (1) 71-77
• 8 Timmermans F, Van Hauwermeiren F, De Smedt M , et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27 (7) 1572-1579
• 9 Gulati R, Jevremovic D, Peterson TE , et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93 (11) 1023-1025
• 10 Urbich C, Aicher A, Heeschen C , et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39 (5) 733-742
• 11 Zentilin L, Tafuro S, Zacchigna S , et al. Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006; 107 (9) 3546-3554
• 12 Aicher A, Rentsch M, Sasaki K , et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007; 100 (4) 581-589
• 13 Pauk N, Klimesova S, Kara J, Topinka J, Labaj J. The relevance of monitoring of antibodies against the polycyclic aromatic hydrocarbon (PAH) and PAH-DNA adducts in serum in relation to lung cancer and chronic obstructive pulmonary disease (COPD). Neoplasma 2013; 60 (2) 182-187
• 14 Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res 2011; 12: 45
• 15 Schiavon M, Fadini GP, Lunardi F , et al. Increased tissue endothelial progenitor cells in end-stage lung diseases with pulmonary hypertension. J Heart Lung Transplant 2012; 31 (9) 1025-1030
• 16 Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J 2010; 35 (2) 418-425
• 17 Totlandsdal AI, Låg M, Lilleaas E, Cassee F, Schwarze P. Differential proinflammatory responses induced by diesel exhaust particles with contrasting PAH and metal content. Environ Toxicol 2013;
• 18 Diller GP, van Eijl S, Okonko DO , et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008; 117 (23) 3020-3030
• 19 Nagaya N, Kyotani S, Uematsu M , et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004; 109 (3) 351-356
• 20 Heissig B, Hattori K, Dias S , et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109 (5) 625-637
• 21 Marsboom G, Pokreisz P, Gheysens O , et al. Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells 2008; 26 (4) 1017-1026
• 22 Toshner M, Morrell NW. Endothelial progenitor cells in pulmonary hypertension - dawn of cell-based therapy?. Int J Clin Pract Suppl 2010; ; ( (165) 7-12
• 23 Issan Y, Hochhauser E, Guo A , et al. Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia. Prostaglandins Other Lipid Mediat 2013; 100–101: 15-21
• 24 Fadini GP, Schiavon M, Cantini M, Avogaro A, Agostini C. Circulating CD34+ cells, pulmonary hypertension, and myelofibrosis. Blood 2006; 108 (5) 1776-1777 , author reply 1777
• 25 Takahashi T, Suzuki S, Kubo H, Yamaya M, Kurosawa S, Kato M. Impaired endothelial progenitor cell mobilization and colony-forming capacity in chronic obstructive pulmonary disease. Respirology 2011; 16 (4) 680-687